Skip to content

Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery

Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery: A Double-Blind Randomized Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06489327
Enrollment
120
Registered
2024-07-05
Start date
2026-07-12
Completion date
2026-12-15
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preoperative Anxiety

Keywords

preoperative anxiety, general anesthesia, major surgery, oral melatonin, placebo, premedication

Brief summary

Preoperative anxiety is a common issue in pediatric anesthesia. Children often experience anxiety and uneasiness due to uncertain outcomes. Surgery and anesthesia are among the most traumatic experiences for children, often considered anxiety-inducing medical treatments. Because they lack control over their environment and circumstances, children undergoing medical procedures typically experience significant unease or anxiety. Several studies have reported that 50%-80% of children experience preoperative anxiety. In order to reduce kids anxiety intensity, several measures are utilized. These strategies are either pharmacological, psychological, or behavioural. Benzodiazepines are popular drugs that can reduce anxiety in children. The most used one in premedication is midazolam. It is a rapid-acting benzodiazepine that has a short elimination half-life. It has sedative, anxiolytic, hypnotic, and anterograde amnesic effects. Midazolam, on the other hand, might have a number of negative consequences, including paradoxical reactions, interactions with opioids, excessive sedation, disorientation, and reduced psychomotor performance. Melatonin enhances anti-nociceptive effects, most prominently through the modulation of MT1/MT2 receptors in the brain and spinal cord. In addition, it has been demonstrated that melatonin can interact with additional receptors, including those in the GABAergic system, the nitric oxide (NO)arginine route, the N-Methyl-D-aspartate (NMDA) system, and the dopaminergic system, to produce anti-nociceptive and anti-allodynic effects.

Interventions

DRUGmelatonin (Circadin ®) 0.2 mg/kg

Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.

DRUGmelatonin (Circadin ®) 0.4 mg/kg

Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.

DRUGplacebo group

Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.

Sponsors

Al-Ayen Iraqi University
CollaboratorOTHER
Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
4 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Patients of either sex * age from 4 to 14 years * Patients with American society Anesthesiologist physical status I and II * Patients undergoing elective surgeries

Exclusion criteria

* ASA more than III * Drug allergy. * Gastrointestinal disorders.

Design outcomes

Primary

MeasureTime frameDescription
preoperative anxiety24 hoursThe child's anxiety level will be assessed by Visual analogue scale-anxiety (VAS-A). The VAS-A consists of a 100 mm horizontal line; the left edge of the line is marked as calm, while the other end shows maximum anxiety. The patients were asked to assess their own anxiety and mark it on the anxiety line.

Secondary

MeasureTime frameDescription
preoperative sedation24 hoursThe sedation level will be assessed using Ramsay Sedation Scale. It divides a patient's level of sedation into six categories ranging from severe agitation at 1 to deep coma at 6.

Countries

Egypt, Iraq

Contacts

Primary ContactNeveen Kohaf, Ph.D
nevenabdo@azhar.edu.eg01060383012

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026